PreludeDx receives FDA breakthrough device designation for AidaBREAST® RNA-seq based early-stage invasive breast cancer assay (opens in new tab)

Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the AidaBREAST® test. AidaBREAST provides individualized prognostic risk assessment and predicts the benefit of radiation therapy (RT) for women diagnosed with early-stage invasive breast cancer. The test ...